Nadia Kirmani

Stanford MD/MS Candidate

Palo Alto, California, United States

About

I am an MD/MS candidate at Stanford University School of Medicine with interests in oncology, translational research, and improving equitable access to care. My research focuses on cancer outcomes, with an emphasis on treatment response, metastatic patterns, and early-onset disease. In parallel, I lead initiatives aimed at improving care delivery for underserved populations. I am interested in how clinical care, data, and systems-level interventions can be integrated to improve patient outcomes.

Experience

  • Stroke Advocate, Speakers Bureau at Stroke Onwards
    Nov 2025 - Present · 8 mos

    Advocating for stroke survivors through storytelling and public engagement as a member of the Stroke Onward Speakers Bureau. Support initiatives aimed at improving survivor-centered care and access to rehabilitation resources. Recently authored an op-ed on stroke advocacy in The Stanford Daily, emphasizing the need for equitable, longitudinal support beyond acute care: https://stanforddaily.com/2025/11/12/when-the-neurologist-works-from-home/

  • Stanford University School of Medicine (1 yr 4 mos)
    • SHINE Project Co-Lead
      Oct 2025 - Present · 9 mos

      Developed SHINE (Safety & Health in Nail-Care Environments), a community-centered initiative aimed at reducing UV and chemical exposure among nail salon workers and clients. Designed occupational health interventions, including safety training, PPE toolkits, and educational resources to promote safer manicure practices. Currently developing implementation strategy and community partnerships to support integration into salon workflows. Funded by the Stanford Primary Care and Population Health Community Impact Mini-Grant.

    • Clinical Researcher, GI Oncology
      Oct 2025 - Present · 9 mos

      Conducting population-based and retrospective research using SEER data to examine disparities in gastrointestinal cancer outcomes under Dr. Shruti Patel. Performing statistical analyses to evaluate demographic and clinical factors associated with disease presentation and survival. Lead author on ongoing manuscript preparation; abstracts accepted at ASCO Annual Meeting 2026.

    • Masters in Translational Research and Applied Medicine Capstone
      Sep 2025 - Present · 10 mos

      Investigating MYC-driven immune evasion in pediatric T-cell acute lymphoblastic leukemia using transcriptomic approaches. Developing a multi-cohort framework to characterize immune microenvironment states across disease progression, with a focus on identifying clinically relevant biomarkers of treatment resistance. Recipient of Med Scholars funding (Fall 2025 - Spring 2027).

  • Havenly Co-Founder at Stanford's Markaz Resource Center
    Jun 2025 - Present · 1 yr 1 mo

    Co-founded Havenly, a digital health platform connecting immigrant families to culturally and linguistically concordant providers. Leading development of a multilingual provider-matching tool and conducting community needs assessment to improve access to care. Funded by the Stanford Markaz Graduate Student Mini-Grant.

  • Stanford University School of Medicine (1 yr 8 mos)
    • Student Researcher
      Aug 2023 - Aug 2024 · 1 yr 1 mo

      Conducted literature review and contributed to development of scoping review and policy briefs on cancer health inequities under Dr. Alyce Adams. Engaged in stakeholder meetings and supported ongoing research efforts to inform equitable resource allocation in oncology care.

    • Medical Scholars Researcher
      Jan 2023 - Aug 2024 · 1 yr 8 mos

      Analyzed clinical outcomes of lymphoma patients treated with CAR T-cell therapy, including treatment response and survival, under Dr. David Miklos. Performed statistical modeling in R to evaluate predictors of clinical outcomes, and co-authored publication in Blood Advances.

  • Research Laboratory Technician at Dana-Farber Cancer Institute
    Sep 2019 - Mar 2022 · 2 yrs 7 mos

    Conducted translational cancer research in the laboratory of Eric Fischer at Dana-Farber Cancer Institute, focusing on targeted protein degradation as a therapeutic strategy. Performed experimental work, including assay development and biochemical analyses, to investigate mechanisms of protein degradation and therapeutic targeting. Co-authored multiple publications arising from this work.